BACKGROUND Hemodialysis patients are prone to constipation, which can adversely affect their quality of life (QOL). Elobixibat, a highly selective inhibitor of the ileal bile acid transporter, can increase the bile acid level in the colon and, subsequently, enhance colonic motility and secretion. In hemodialysis patients with chronic constipation, it may have a novel action mechanism. However, the effect of elobixibat on such patients' QOL had not been reported. This study aimed to evaluate the effect of elobixibat on the QOL of hemodialysis patients with chronic constipation. METHODS This was a multicenter, observational study that used the Japanese version of the Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaire on 27 patients (18 men and nine women, age range 47-90 years), who satisfied the Rome 3 diagnostic criteria for functional constipation and were already taking other drugs for constipation. These patients were administered elobixibat 10 mg/day and were asked to respond to the PAC-QOL questionnaire at baseline and after 4 weeks. Bayesian statistics were used to confirm our results. RESULTS The number of spontaneous bowel movements per week increased significantly from 2.6 ± 1.2 to 4.1 ± 2.1 (p < 0.001), and the Bristol Stool Form Scale score significantly improved from 1.9 ± 0.8 to 3.6 ± 0.7 (p < 0.001). The Cronbach's alpha was 0.95, and the Guttman split-half reliability coefficient was 0.90. There were significant decreases in the physical discomfort scores from 1.94 ± 0.79 to 0.97 ± 0.72 (p < 0.001); psychosocial discomfort from 1.16 ± 0.93 to 0.63 ± 0.58 (p < 0.001); worries/ concerns from 1.84 ± 0.73 to 1.27 ± 0.59 (p < 0.001), and satisfaction from 2.79 ± 0.61 to 1.98 ± 0.77 (p < 0.001). The total PAC-QOL score significantly decreased from 1.83 ± 0.79 to 1.17 ± 0.56 (p < 0.001). Bayesian statistics confirmed the results' significance. CONCLUSIONS Elobixibat reduced the PAC-QOL scores for hemodialysis patients with chronic constipation and improved the patients' QOL. It may serve as a new option for treating constipation in hemodialysis patients.

中文翻译：

---

Elobixibat缓解了血液透析患者的慢性便秘：一项基于问卷的研究。

背景技术血液透析患者容易出现便秘，这会对他们的生活质量（QOL）产生不利影响。Elobixibat是回肠胆汁酸转运蛋白的高度选择性抑制剂，可增加结肠中的胆汁酸水平，并随后增强结肠运动性和分泌。在患有慢性便秘的血液透析患者中​​，它可能具有新的作用机制。但是，尚未报告艾洛昔布对这类患者的生活质量的影响。本研究旨在评估伊洛比昔布对慢性便秘血液透析患者的生活质量的影响。方法这是一项多中心的观察性研究，使用日语版的便秘患者生活质量评估问卷（PAC-QOL）对27例患者（18例男性和9例女性，年龄在47-90岁）进行了研究，他们符合功能性便秘的罗马3诊断标准，并且已经在服用其他药物用于便秘。这些患者每天接受10 mg依比昔巴特（elobixibat）的治疗，并要求他们在基线时和4周后对PAC-QOL问卷做出回应。贝叶斯统计被用来确认我们的结果。结果每周自发排便次数从2.6±1.2显着增加到4.1±2.1（p <0.001），而布里斯托尔凳形式量表评分从1.9±0.8显着提高到3.6±0.7（p <0.001）。克朗巴赫（Cronbach）α为0.95，古特曼（Guttman）对分半可靠性系数为0.90。身体不适评分从1.94±0.79显着降低至0.97±0.72（p <0.001）；社会心理不适从1.16±0.93到0.63±0.58（p <0.001）; 从1.84±0.73到1.27±0.59（p <0.001）的担忧/担忧，从2.79±0.61到1.98±0.77（p <0.001）的满意度。PAC-QOL总分从1.83±0.79显着降低到1.17±0.56（p <0.001）。贝叶斯统计证实了结果的重要性。结论Elobixibat降低了慢性便秘血液透析患者的PAC-QOL评分，并改善了患者的QOL。它可以作为治疗血液透析患者便秘的新选择。结论Elobixibat降低了慢性便秘血液透析患者的PAC-QOL评分，并改善了患者的QOL。它可以作为治疗血液透析患者便秘的新选择。结论Elobixibat降低了慢性便秘血液透析患者的PAC-QOL评分，并改善了患者的QOL。它可以作为治疗血液透析患者便秘的新选择。